PTHS Stock Analysis: Buy, Sell, or Hold?
PTHS - Pelthos Therapeutics Inc.
$26.15
-0.57 (-2.13%)
▼
5d:
-2.61%
30d:
+13.62%
90d:
+20.79%
BUY
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When PTHS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PTHS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PTHS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PTHS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PTHS is currently trading at $26.15, which is considered extended relative to its 30-day fair value range of $22.99 to $26.06.
Technical Outlook: Technically, PTHS is showing sideways momentum. Immediate support is located at $24.48, while resistance sits at $29.64.
Market Sentiment: PTHS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.14 (+113.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PTHS is showing sideways momentum. Immediate support is located at $24.48, while resistance sits at $29.64.
Market Sentiment: PTHS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.14 (+113.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$22.99 -
$26.06
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 113.9% below Wall St target ($57.14)
Trading Range Analysis
30-Day Trading Range
$22.99 -
$26.06
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.48
Resistance Level
$29.64
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-254.48
Wall Street Target
$57.14
(+113.9%)
Profit Margin
-257.9%
Share & Embed Analysis
Last updated: May 18, 2026 4:22 PM ET
Data refreshes hourly during market hours. Next update: 5:22 PM
Data refreshes hourly during market hours. Next update: 5:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTHS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ezra M Friedberg
SELL
558 shares
2026-04-02
Peter Greenleaf
SELL
797 shares
2026-04-02
Richard Malamut
SELL
590 shares
2026-04-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 45 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 50 HOLD |
